TransCode Therapeutics Statistics
Want to see RNAZ full AI Analyst Report?
TransCode Therapeutics (RNAZ) Stock Statistics & Valuation Metrics
Total Valuation
TransCode Therapeutics has a market cap or net worth of $25.23M. The enterprise value is -$2.30M.
- Market Cap
- $25.23M
- Enterprise Value
- -$2.30M
Share Statistics
TransCode Therapeutics has 16,930,738 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 16,930,738
- Owned by Insiders
- 83.82%
- Owned by Institutions
- 0.23%
Financial Efficiency
TransCode Therapeutics’s return on equity (ROE) is -3.35 and return on invested capital (ROIC) is -17.61%.
- Return on Equity (ROE)
- -3.35
- Return on Assets (ROA)
- -0.21
- Return on Invested Capital (ROIC)
- -17.61%
- Return on Capital Employed (ROCE)
- -0.18
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.89M
- Employee Count
- 12
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of TransCode Therapeutics is -0.03. TransCode Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.03
- PS Ratio
- 0.00
- PB Ratio
- 0.01
- Price to FCF
- -0.07
- Price to Operating Cash Flow
- -0.06
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, TransCode Therapeutics had revenue of 0 and earned -34.66M in profits. Earnings per share was -52.59.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -27.98M
- Pretax Income
- -34.44M
- Net Income
- -34.66M
- EBITDA
- -34.31M
- Earnings Per Share (EPS)
- -52.59
Cash Flow
In the last 12 months, operating cash flow was -22.61M and capital expenditures -6,660, giving a free cash flow of -22.61M billion.
- Operating Cash Flow
- -22.61M
- Free Cash Flow
- -22.61M
- Free Cash Flow per Share
- -24.13
Dividends & Yields
TransCode Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1352.07%
- Earnings Yield
- -2889.34%
Stock Price Statistics
- Beta
- 2.62
- 52-Week Price Change
- -83.96%
- 50-Day Moving Average
- 1.73
- 200-Day Moving Average
- 5.88
- Relative Strength Index (RSI)
- 35.28
- Average Volume (3m)
- 54.81K
Important Dates
TransCode Therapeutics upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Mar 28, 2025
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
TransCode Therapeutics as a current ratio of 6.29, with Debt / Equity ratio of 0.00%
- Current Ratio
- 6.29
- Quick Ratio
- 6.29
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.52
- Interest Coverage Ratio
- -4229.15
Taxes
In the past 12 months, TransCode Therapeutics has paid 226.07K in taxes.
- Income Tax
- 226.07K
- Effective Tax Rate
- -0.01
Enterprise Valuation
TransCode Therapeutics EV to EBITDA ratio is 0.14, with an EV/FCF ratio of 0.27.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.14
- EV to Free Cash Flow
- 0.27
- EV to Operating Cash Flow
- 0.27
Balance Sheet
TransCode Therapeutics has $8.38M in cash and marketable securities with $652.41K in debt, giving a net cash position of $7.73M billion.
- Cash & Marketable Securities
- $8.38M
- Total Debt
- $652.41K
- Net Cash
- $7.73M
- Net Cash Per Share
- $0.46
- Tangible Book Value Per Share
- -$1.80
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for TransCode Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 86.74%
Scores
- Smart Score
- ―
- AI Score
- 49
